Researchers at the Perelman School of Medicine at the University of Pennsylvania have uncovered a fundamental rule governing how DNA is physically arranged inside the cell nucleus, and how disruptions to that organization can contribute to human disease, specifically Friedreich's ataxia. The study, published in a peer-reviewed journal, reveals that the physical folding of DNA can silence a key gene, FXN, which is responsible for producing frataxin, a protein essential for mitochondrial function.
Friedreich's ataxia is a rare, inherited neurodegenerative disorder that affects approximately 1 in 50,000 people in the United States. It is caused by a mutation in the FXN gene, leading to reduced frataxin levels. The Penn team discovered that in cells from patients with Friedreich's ataxia, the DNA containing the FXN gene is folded into a compact, inactive structure that prevents the gene from being expressed.
This finding provides a new understanding of how gene silencing can occur through physical changes in DNA architecture, rather than just through chemical modifications. The researchers used advanced imaging and genomic techniques to map the 3D organization of the genome in patient cells, identifying specific loops and folds that correlate with gene activity.
The study's lead author, Dr. [Name not verified], stated that this discovery could lead to new therapeutic approaches that target DNA folding to reactivate the silenced FXN gene. While the research is still in its early stages, it opens up potential avenues for treating Friedreich's ataxia and possibly other diseases caused by similar DNA folding abnormalities.
As of May 2026, no clinical trials have been announced based on this specific mechanism, but the research provides a foundational understanding that could inform future drug development. The findings were confirmed through multiple experimental methods and are considered robust by the scientific community.
